166 related articles for article (PubMed ID: 11804070)
1. Very late appearance of acute graft-versus-host disease after tapering immunosuppression.
Wollina U; Sayer HG; Wollina K; Graefe T
J Dermatol; 2001 Dec; 28(12):734-6. PubMed ID: 11804070
[TBL] [Abstract][Full Text] [Related]
2. Graft-versus-host disease: case report and review of literature.
Jing X; Halat S; Meleg-Smith S
J La State Med Soc; 2006; 158(1):20-4. PubMed ID: 16602481
[TBL] [Abstract][Full Text] [Related]
3. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
4. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
5. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
Lin Q; Dong M; Wang QM; Wen JY; Wu XY
Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
[TBL] [Abstract][Full Text] [Related]
6. Induction of graft-versus-autoimmune (GVA) disease effect against refractory psoriasis by complete donor-type chimerism and graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Kojima R; Kami M; Kim SW; Murashige N; Kishi Y; Hori A; Imataki O; Hamaki T; Sakiyama M; Masuo S; Fujisawa Y; Makimoto A; Heike Y; Tanosaki R; Takaue Y
Bone Marrow Transplant; 2003 Aug; 32(4):439-42. PubMed ID: 12900783
[TBL] [Abstract][Full Text] [Related]
7. Histological evaluation of acute mucocutaneous graft-versus-host disease in nonmyeloablative hematologic stem cell transplants with an observation predicting an increased risk of progression to chronic graft-versus-host disease.
Bridge AT; Nelson RP; Schwartz JE; Mirowski GW; Billings SD
Am J Dermatopathol; 2007 Feb; 29(1):1-6. PubMed ID: 17284954
[TBL] [Abstract][Full Text] [Related]
8. Severe eosinophilia as a manifestation of acute graft-versus-host disease.
Paralkar VR; Goradia A; Luger SM; Loren AW
Oncology; 2008; 75(3-4):134-6. PubMed ID: 18791329
[TBL] [Abstract][Full Text] [Related]
9. Anti-leukemic effect of graft-versus-host disease on bone marrow and extramedullary relapses in acute leukemia.
Lee JH; Choi SJ; Lee JH; Seol M; Lee YS; Ryu SG; Park CJ; Chi HS; Lee MS; Yun S; Lee JS; Lee KH
Haematologica; 2005 Oct; 90(10):1380-8. PubMed ID: 16219575
[TBL] [Abstract][Full Text] [Related]
10. Rapid tapering of cyclosporin to maximise the graft-versus-leukaemia effect.
Shaw PJ; Afify Z
Bone Marrow Transplant; 1999 Mar; 23(6):632-3. PubMed ID: 10217198
[No Abstract] [Full Text] [Related]
11. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
13. Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients.
Shaiegan M; Iravani M; Babaee GR; Ghavamzadeh A
Transpl Immunol; 2006 Jan; 15(3):223-7. PubMed ID: 16431290
[TBL] [Abstract][Full Text] [Related]
14. Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission.
Fouillard L; Labopin M; Gratwohl A; Gluckman E; Frassoni F; Beelen DW; Willemze R; Montserrat E; Blaise D; Atienza AI; Sierra J; Santos M; Gorin NC; Rocha V;
Haematologica; 2008 Jun; 93(6):834-41. PubMed ID: 18469352
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment with steroids of upper gastrointestinal acute graft vs. host disease after hematopoietic stem cell transplantation.
Nishi T; Okazaki K; Fujii S; Uchida K; Uose S; Nakase H; Ohana M; Nishihara T; Chiba T
Endoscopy; 2001 Nov; 33(11):985-7. PubMed ID: 11668409
[TBL] [Abstract][Full Text] [Related]
16. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse.
Aversa F; Terenzi A; Tabilio A; Falzetti F; Carotti A; Ballanti S; Felicini R; Falcinelli F; Velardi A; Ruggeri L; Aloisi T; Saab JP; Santucci A; Perruccio K; Martelli MP; Mecucci C; Reisner Y; Martelli MF
J Clin Oncol; 2005 May; 23(15):3447-54. PubMed ID: 15753458
[TBL] [Abstract][Full Text] [Related]
17. Induction of late graft-versus-host disease in a patient post-allogeneic stem cell transplantation by progesterone in conjunction with donor lymphocyte infusion.
Gesundheit B; Shapira MY; Maly A; Samuel S; Budowski E; Or R
Leuk Res; 2008 Mar; 32(3):501-3. PubMed ID: 17727947
[TBL] [Abstract][Full Text] [Related]
18. Using human adipose tissue-derived mesenchymal stem cells as salvage therapy for hepatic graft-versus-host disease resembling acute hepatitis.
Fang B; Song Y; Zhao RC; Han Q; Lin Q
Transplant Proc; 2007 Jun; 39(5):1710-3. PubMed ID: 17580228
[TBL] [Abstract][Full Text] [Related]
19. Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapy.
Creamer D; Martyn-Simmons CL; Osborne G; Kenyon M; Salisbury JR; Devereux S; Pagliuca A; Ho AY; Mufti GJ; du Vivier AW
Arch Dermatol; 2007 Sep; 143(9):1157-62. PubMed ID: 17875877
[TBL] [Abstract][Full Text] [Related]
20. New clinical grading system for chronic GVHD predicts duration of systemic immunosuppressive treatment and GVHD-specific and overall survival.
Kim ST; Jung CW; Lee J; Kwon JM; Oh SY; Park BB; Lee HR; Kim HJ; Kim K; Kim WS; Ahn JS; Kang WK; Park K
Bone Marrow Transplant; 2007 Jun; 39(11):711-6. PubMed ID: 17417662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
